DK3917626T3 - Psma-bindende dualmodusradiotracer og terapeutika - Google Patents

Psma-bindende dualmodusradiotracer og terapeutika Download PDF

Info

Publication number
DK3917626T3
DK3917626T3 DK20702636.0T DK20702636T DK3917626T3 DK 3917626 T3 DK3917626 T3 DK 3917626T3 DK 20702636 T DK20702636 T DK 20702636T DK 3917626 T3 DK3917626 T3 DK 3917626T3
Authority
DK
Denmark
Prior art keywords
radiotracer
psma
therapeutics
mode
dual
Prior art date
Application number
DK20702636.0T
Other languages
English (en)
Inventor
Hans-Jürgen Wester
Alexander Josef Wurzer
Matthias Johannes Eiber
Original Assignee
Technische Univ Muenchen Klinikum Rechts Der Isar
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Univ Muenchen Klinikum Rechts Der Isar, Univ Muenchen Tech filed Critical Technische Univ Muenchen Klinikum Rechts Der Isar
Application granted granted Critical
Publication of DK3917626T3 publication Critical patent/DK3917626T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008Peptides; Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Circuits Of Receivers In General (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nuclear Medicine (AREA)
  • Toys (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
DK20702636.0T 2019-01-30 2020-01-30 Psma-bindende dualmodusradiotracer og terapeutika DK3917626T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19154500 2019-01-30
PCT/EP2020/052248 WO2020157177A1 (en) 2019-01-30 2020-01-30 Psma binding dual mode radiotracer and therapeutic

Publications (1)

Publication Number Publication Date
DK3917626T3 true DK3917626T3 (da) 2023-08-28

Family

ID=65268810

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20702636.0T DK3917626T3 (da) 2019-01-30 2020-01-30 Psma-bindende dualmodusradiotracer og terapeutika
DK23167668.5T DK4249456T3 (da) 2019-01-30 2020-01-30 Psma-bindende dobbeltfungerende radioaktivt sporstof og terapeutikum

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK23167668.5T DK4249456T3 (da) 2019-01-30 2020-01-30 Psma-bindende dobbeltfungerende radioaktivt sporstof og terapeutikum

Country Status (19)

Country Link
US (2) US12357711B2 (da)
EP (2) EP3917626B1 (da)
JP (2) JP7528100B2 (da)
KR (1) KR102850587B1 (da)
CN (2) CN113677400B (da)
AU (2) AU2020213678B2 (da)
BR (1) BR112021014933A2 (da)
CA (1) CA3128401A1 (da)
DK (2) DK3917626T3 (da)
EA (1) EA202191691A1 (da)
ES (2) ES2995872T3 (da)
FI (2) FI4249456T3 (da)
HU (2) HUE069264T2 (da)
IL (2) IL303421A (da)
MX (1) MX2021008999A (da)
PL (2) PL4249456T3 (da)
PT (2) PT3917626T (da)
SG (1) SG11202108109RA (da)
WO (1) WO2020157177A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ760537A (en) 2017-07-28 2026-01-30 Univ Muenchen Tech Dual mode radiotracer and -therapeutics
WO2020157177A1 (en) * 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic
GB202005282D0 (en) 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
JP2023539990A (ja) * 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
US20230277698A1 (en) * 2020-07-23 2023-09-07 Technische Universität München Silicon-containing ligand compounds
EP4023250A1 (en) 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
WO2022171901A1 (en) * 2021-02-15 2022-08-18 Technische Universität München Dual mode radiotracer and therapeutics
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
IL310066A (en) * 2021-08-05 2024-03-01 Technische Universit?T M?Nchen Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CA3232149A1 (en) * 2021-09-28 2023-04-06 Antelope Surgical Solutions, Inc. Multifunctional compounds for use in medical imaging and therapy
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination
GB202318958D0 (en) * 2023-12-12 2024-01-24 King S College London Compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669127C (en) * 2006-11-08 2016-09-13 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
NZ612327A (en) * 2010-12-22 2015-03-27 Ge Healthcare Ltd Her2 binding peptides labelled with a 18f - containing organosilicon compound
CN102626522B (zh) 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR102724812B1 (ko) 2017-04-05 2024-11-01 코넬 유니버시티 영상화 및 항종양 치료요법에 유용한 조정 가능한 약동학을 갖는 삼작용성 작제물
NZ760537A (en) * 2017-07-28 2026-01-30 Univ Muenchen Tech Dual mode radiotracer and -therapeutics
SMT202400439T1 (it) * 2017-12-11 2024-11-15 Univ Muenchen Tech Ligandi di psma per la formazione di immagini e endoradioterapia
WO2020157177A1 (en) 2019-01-30 2020-08-06 Technische Universität München Psma binding dual mode radiotracer and therapeutic

Also Published As

Publication number Publication date
CN116675730A (zh) 2023-09-01
KR20210153037A (ko) 2021-12-16
ES2995872T3 (en) 2025-02-11
EP4249456A3 (en) 2023-10-11
IL303421A (en) 2023-08-01
IL284958A (en) 2021-09-30
EA202191691A1 (ru) 2021-11-01
US20220096668A1 (en) 2022-03-31
PT4249456T (pt) 2024-12-02
JP2024073651A (ja) 2024-05-29
SG11202108109RA (en) 2021-08-30
AU2020213678A1 (en) 2021-08-12
EP3917626B1 (en) 2023-05-31
EP4249456B1 (en) 2024-09-04
US12357711B2 (en) 2025-07-15
CN113677400A (zh) 2021-11-19
AU2023203501B2 (en) 2024-11-14
ES2953196T3 (es) 2023-11-08
AU2023203501A1 (en) 2023-07-06
PL3917626T3 (pl) 2023-11-27
PT3917626T (pt) 2023-08-23
IL284958B1 (en) 2026-01-01
CA3128401A1 (en) 2020-08-06
HUE063038T2 (hu) 2023-12-28
FI3917626T3 (fi) 2023-08-17
DK4249456T3 (da) 2024-12-02
JP7763885B2 (ja) 2025-11-04
FI4249456T3 (fi) 2024-12-07
JP7528100B2 (ja) 2024-08-05
WO2020157177A1 (en) 2020-08-06
PL4249456T3 (pl) 2025-03-31
BR112021014933A2 (pt) 2021-10-05
EP3917626A1 (en) 2021-12-08
EP4249456A2 (en) 2023-09-27
JP2022523727A (ja) 2022-04-26
CN113677400B (zh) 2023-12-01
HUE069264T2 (hu) 2025-02-28
KR102850587B1 (ko) 2025-08-27
IL284958B2 (en) 2026-05-01
AU2020213678B2 (en) 2024-05-30
MX2021008999A (es) 2021-11-04
US20250295819A1 (en) 2025-09-25

Similar Documents

Publication Publication Date Title
DK3658194T3 (da) Kombineret radiotracer og -terapeutika
IL285178A (en) Compounds and uses thereof
DK3737765T4 (da) Forstærkede immunceller med dobbelt shrna og sammensætning dermed
DK3917616T3 (da) Heterocykliske forbindelser og anvendelse deraf
IL284835A (en) Pharmaceutical combination comprising tno155 and ribociclib
EP3900434C0 (en) RESUMPTION-SUSPENSION IN A CONDITIONAL TRANSFER
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
DK4461734T3 (da) Tyk2-hæmmere og anvendelser deraf
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
IL292692A (en) Mrgprx2 antagonists and uses thereof
DK3610005T3 (da) Peptidligase og anvendelse deraf
PL3917626T3 (pl) Dwutrybowy radioznacznik i terapeutyk wiążący psma
DK3280432T3 (da) Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3603620T3 (da) Liposomsammensætning og farmaceutisk sammensætning
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
IL284799A (en) Tyk2 inhibitors and uses thereof
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
DK3922266T3 (da) Toll-like-receptor-7- eller -8-agonist-kolesterolkompleks og anvendelse deraf
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
IL292693A (en) Mrgprx2 antagonists and uses thereof
DK4034535T3 (da) Aza-quinolinforbindelser og anvendelser deraf
DK3892621T3 (da) Haloallylaminforbindelser og anvendelse deraf